Do Different Diabetes Drugs Affect Heart Rhythm and Nerve Function Differently? The GRADE Trial
In the GRADE randomized trial, liraglutide and three other diabetes drugs showed differences in ECG abnormalities and cardiac autonomic neuropathy over 4 years.
Quick Facts
What This Study Found
Different glucose-lowering drugs showed varying effects on ECG abnormalities and cardiac autonomic neuropathy prevalence over 4 years in the GRADE trial.
Key Numbers
N=4,769; baseline ECG abnormalities 57.1%; baseline CAN 52.8%; year 4 major ECG abnormalities: liraglutide 9% vs non-liraglutide 13% (P=0.03).
How They Did This
Randomized controlled trial (GRADE) with resting ECGs and heart rate variability analysis at baseline, 2, and 4 years in 4,769 participants.
Why This Research Matters
Heart rhythm problems and autonomic neuropathy are underrecognized diabetes complications — knowing which drugs affect them matters for treatment selection.
The Bigger Picture
GRADE is one of the largest comparative diabetes drug trials, and this cardiac substudy adds important safety and efficacy data beyond glycemic control.
What This Study Doesn't Tell Us
ECG analysis was a secondary outcome of the GRADE trial — not powered specifically for this comparison.
Questions This Raises
- ?Does liraglutide have specific cardioprotective effects on autonomic function?
- ?Should ECG monitoring be routine when choosing between diabetes drugs?
Trust & Context
- Key Stat:
- 4,769 participants GRADE randomized trial comparing ECG outcomes across 4 diabetes drug arms over 4 years
- Evidence Grade:
- Substudy of a large randomized controlled trial — high-quality design but ECG outcomes were secondary endpoints.
- Study Age:
- Published in 2025 in Diabetes Care, part of the ongoing GRADE trial publications.
- Original Title:
- Differences in Prevalence and Incidence of Electrocardiogram Abnormalities and Cardiovascular Autonomic Neuropathy Among Randomized Glucose-Lowering Treatments in Early Type 2 Diabetes: The Glycemia Reduction Approaches in Diabetes (GRADE) Cohort.
- Published In:
- Diabetes care, 48(11), 1960-1970 (2025)
- Authors:
- Pop-Busui, Rodica(5), Rosin, Samuel P(2), Butera, Nicole M(2), Krause-Steinrauf, Heidi, Abou Assi, Hiba, Garg, Rajesh K, Inzucchi, Silvio E, Katona, Aimee, McGill, Janet B, Mudaliar, Sunder, Schade, David S, Seaquist, Elizabeth R, Tiktin, Margaret, Soliman, Elsayed Z, Green, Jennifer B
- Database ID:
- RPEP-13082
Evidence Hierarchy
Frequently Asked Questions
Do diabetes drugs affect heart rhythm?
The GRADE trial found differences in ECG abnormalities between four diabetes drugs over 4 years, suggesting cardiac effects vary by medication.
What is cardiac autonomic neuropathy?
Damage to the nerves controlling heart rate — it is a diabetes complication that affects heart rate variability and cardiovascular risk.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13082APA
Pop-Busui, Rodica; Rosin, Samuel P; Butera, Nicole M; Krause-Steinrauf, Heidi; Abou Assi, Hiba; Garg, Rajesh K; Inzucchi, Silvio E; Katona, Aimee; McGill, Janet B; Mudaliar, Sunder; Schade, David S; Seaquist, Elizabeth R; Tiktin, Margaret; Soliman, Elsayed Z; Green, Jennifer B. (2025). Differences in Prevalence and Incidence of Electrocardiogram Abnormalities and Cardiovascular Autonomic Neuropathy Among Randomized Glucose-Lowering Treatments in Early Type 2 Diabetes: The Glycemia Reduction Approaches in Diabetes (GRADE) Cohort.. Diabetes care, 48(11), 1960-1970. https://doi.org/10.2337/dc25-1087
MLA
Pop-Busui, Rodica, et al. "Differences in Prevalence and Incidence of Electrocardiogram Abnormalities and Cardiovascular Autonomic Neuropathy Among Randomized Glucose-Lowering Treatments in Early Type 2 Diabetes: The Glycemia Reduction Approaches in Diabetes (GRADE) Cohort.." Diabetes care, 2025. https://doi.org/10.2337/dc25-1087
RethinkPeptides
RethinkPeptides Research Database. "Differences in Prevalence and Incidence of Electrocardiogram..." RPEP-13082. Retrieved from https://rethinkpeptides.com/research/pop-busui-2025-differences-in-prevalence-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.